Quick Answer
Xenon Pharmaceuticals Inc. reported Diluted EPS of $4.36 per share (loss) for fiscal year 2025.
Xenon Pharmaceuticals Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.36 | -44.9% |
| 2024 | -$3.01 | -10.3% |
| 2023 | -$2.73 | -32.5% |
| 2022 | -$2.06 | -16.4% |
| 2021 | -$1.77 | -118.5% |
| 2020 | -$0.81 | +50.3% |
| 2018 | -$1.63 | +5.2% |
| 2017 | -$1.72 | -16.2% |
| 2016 | -$1.48 | -34.5% |
| 2015 | -$1.10 | -133.5% |
| 2014 | $3.28 | +71.7% |
| 2013 | $1.91 | +159.0% |
| 2012 | -$3.24 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.15 | -42.0% | -7.5% |
| June 30, 2025 | -$1.07 | -42.7% | -28.9% |
| March 31, 2025 | -$0.83 | -33.9% | -2.5% |
| September 30, 2024 | -$0.81 | -11.0% | -8.0% |
| June 30, 2024 | -$0.75 | -4.2% | -21.0% |
| March 31, 2024 | -$0.62 | +1.6% | +15.1% |
| September 30, 2023 | -$0.73 | -28.1% | -1.4% |
| June 30, 2023 | -$0.72 | -30.9% | -14.3% |
- Xenon Pharmaceuticals Inc. showed a decrease of -44.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2012–2025 period, Xenon Pharmaceuticals Inc.’s diluted eps has declined by 34.6% (from $3.24 per share (loss) to $4.36 per share (loss)).
- The most recent figure is from Xenon Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: